Faes Farma, S.A.

BME:FAE Lagerbericht

Marktkapitalisierung: €1.1b

Faes Farma Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Faes FarmaDer Gewinn des Unternehmens wird voraussichtlich um 1.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 1.6% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich sinken um 2% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 11.3% betragen.

Wichtige Informationen

-1.9%

Wachstumsrate der Gewinne

-2.0%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum14.5%
Wachstumsrate der Einnahmen1.6%
Zukünftige Eigenkapitalrendite11.3%
Analystenabdeckung

Low

Zuletzt aktualisiert29 Apr 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01
Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Recent updates

Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Mar 01
Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts Think

Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Dec 18
Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316

Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Dec 04
Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316

Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

Nov 24
Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?

Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

May 03
Here's Why Faes Farma (BME:FAE) Can Manage Its Debt Responsibly

Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Sep 21
Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?

Is Faes Farma (BME:FAE) A Risky Investment?

Aug 03
Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Jun 17
Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings Growth

Is Faes Farma (BME:FAE) Using Too Much Debt?

Mar 27
Is Faes Farma (BME:FAE) Using Too Much Debt?

Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Dec 13
Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14

Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Nov 29
Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17

Is Faes Farma (BME:FAE) A Risky Investment?

Sep 21
Is Faes Farma (BME:FAE) A Risky Investment?

Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This Year

Is Faes Farma (BME:FAE) Using Too Much Debt?

May 01
Is Faes Farma (BME:FAE) Using Too Much Debt?

Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Apr 07
Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)

Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Mar 22
Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?

Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Mar 06
Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak Foundations

Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

Feb 22
Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their Investment

I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Jan 16
I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With Ease

Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Dec 08
Faes Farma (BME:FAE) Seems To Use Debt Rather Sparingly

Gewinn- und Umsatzwachstumsprognosen

BME:FAE - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20264998994N/A3
12/31/20254909279N/A3
12/31/20244769055N/A3
3/31/202448295N/AN/AN/A
12/31/202347392-1101N/A
9/30/202347290N/AN/AN/A
6/30/202346990-997N/A
3/31/202346791N/AN/AN/A
12/31/20224628926107N/A
9/30/202246086N/AN/AN/A
6/30/20224668850113N/A
3/31/202244988N/AN/AN/A
12/31/2021429822080N/A
9/30/202141681N/AN/AN/A
6/30/202139874856N/A
3/31/202139473N/AN/AN/A
12/31/2020411735378N/A
9/30/202040877N/AN/AN/A
6/30/2020407735778N/A
3/31/202040968N/AN/AN/A
12/31/2019383644668N/A
9/30/201937960N/AN/AN/A
6/30/2019363595174N/A
3/31/201935154N/AN/AN/A
12/31/2018340524059N/A
9/30/201833451N/AN/AN/A
6/30/2018330494058N/A
3/31/201830847N/AN/AN/A
12/31/201728241N/A42N/A
9/30/201726639N/AN/AN/A
6/30/201725039N/A43N/A
3/31/201724138N/AN/AN/A
12/31/201623737N/A50N/A
9/30/201622635N/AN/AN/A
6/30/201622234N/A40N/A
3/31/201622032N/AN/AN/A
12/31/201521430N/A41N/A
9/30/201520728N/AN/AN/A
6/30/201520327N/A42N/A
3/31/201519626N/AN/AN/A
12/31/201419825N/A32N/A
9/30/201419523N/AN/AN/A
6/30/201419424N/A20N/A
3/31/201419220N/AN/AN/A
12/31/201319323N/A32N/A
9/30/201319621N/AN/AN/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: FAEFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-1.9% pro Jahr).

Ertrag vs. Markt: FAEFür die nächsten 3 Jahre wird ein Rückgang der Gewinne prognostiziert (-1.9% pro Jahr).

Hohe Wachstumserträge: FAEFür die nächsten 3 Jahre wird mit einem Rückgang der Erträge gerechnet.

Einnahmen vs. Markt: FAEDie Einnahmen des Unternehmens (1.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt Spanish (4.7% pro Jahr).

Hohe Wachstumseinnahmen: FAEDie Einnahmen des Unternehmens (1.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: FAEDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (11.3%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y